Thought Leadership
Status Quo Maintained: FDA Reverses Course on Generic Product Labeling
March 1, 2019
Chad Landmon and Eric Dunbar
FDLI Update

Axinn partner Chad Landmon and associate Eric Dunbar authored the FDLI’s Update article, "Status Quo Maintained: FDA Reverses Course on Generic Product Labeling."

Click here to access the article. Shared with the permission of FDLI.

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.